

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER OF PATENTS AND TRADEMARKS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DAT	E	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/394,020	09/10/1999		CARMEN V. PEPICELLI	HUIP-P01-032	3626
28120	7590 06/0	03/2003			
ROPES & GRAY LLP				EXAMINER	
ONE INTERNATIONAL PLACE BOSTON, MA 02110-2624				ANDRES, J	ANET L
				ART UNIT	PAPER NUMBER
				1646	70
				DATE MAILED: 06/03/2003	,) 0

Please find below and/or attached an Office communication concerning this application or proceeding.

	Ar	plication No.	Applicant(s)				
	. 09	9/394,020	PEPICELLI ET AL.				
Office Action Sum		aminer	Art Unit				
· ·		net L. Andres	1646				
The MAILING DATE of thi			eet with the correspondence address				
Period for Reply							
	COMMUNICATION. the provisions of 37 CFR 1.136(a). te of this communication. ss than thirty (30) days, a reply with e maximum statutory period will ap period for reply will, by statute, caus three months after the mailing date	In no event, however, in the statutory minimun ply and will expire SIX (see the application to become and see the application to be application.	may a reply be timely filed n of thirty (30) days will be considered timely. h) MONTHS from the mailing date of this communication. ome ABANDONED (35 U.S.C. § 133).				
1) Responsive to communic	cation(s) filed on 24 Marc	<u>ch 2003</u> .	•				
2a)⊠ This action is FINAL .	2b)☐ This a	ction is non-final.					
3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.							
Disposition of Claims	2.24 and 25 inlara pandin	a in the applicati					
4) Claim(s) 1,2,4,5,22,24-28							
_ ′	4a) Of the above claim(s) <u>22,34 and 35</u> is/are withdrawn from consideration.						
5) Claim(s) is/are allowed.							
6)⊠ Claim(s) <u>1,2,4,5 and 24-28</u> is/are rejected.							
7) Claim(s) is/are objection		ation rocuiromo					
8) Claim(s) are subject Application Papers	ct to restriction and/or ele	ection requiremen	ιι.,				
9) The specification is objected	ed to by the Examiner.						
10)☐ The drawing(s) filed on	•	or b) objected to	b by the Examiner.				
			abeyance. See 37 CFR 1.85(a).				
11) The proposed drawing corr	· -		•				
If approved, corrected draw	vings are required in reply to	this Office action	•				
12) The oath or declaration is o	objected to by the Exami	ner.					
Priority under 35 U.S.C. §§ 119 an	nd 120						
13) Acknowledgment is made	of a claim for foreign pri	ority under 35 U.	S.C. § 119(a)-(d) or (f).				
a) ☐ All b) ☐ Some * c) ☐	None of:						
1. Certified copies of t	he priority documents ha	ve been receive	d.				
2. Certified copies of the priority documents have been received in Application No.							
3. ☐ Copies of the certification							
application from * See the attached detailed C	n the International Bureau Office action for a list of the						
14) Acknowledgment is made o	of a claim for domestic pr	iority under 35 U	.S.C. § 119(e) (to a provisional application).				
a) The translation of the 15) Acknowledgment is made of		• •					
Attachment(s)			•				
Notice of References Cited (PTO-892) Notice of Draftsperson's Patent Drawii Information Disclosure Statement(s) (F	ng Review (PTO-948)	· <u>—</u>	erview Summary (PTO-413) Paper No(s) cice of Informal Patent Application (PTO-152) er:				
U.S. Patent and Trademark Office PTO-326 (Rev. 04-01)	Office Action	Summary	Part of Paper No. 38				

Art Unit: 1646

RESPONSE TO AMENDMENT

1. Applicant's amendment filed 24 March 2003 is acknowledged. Claims 1, 2, 4, 5, 22, 24-28, 34, and 35 are pending in this application. Claims 22, 34, and 35 are withdrawn from consideration as being drawn to the non-elected invention of modulation by FGF-10 therapeutics. The text of those sections of Title 35, U.S. Code, not included in this action can be found in a prior office action.

Claim Rejections Withdrawn

- 2. The rejection of claims 1-15. 24-33, and 35 under 35 U.S.C. 112, first paragraph, as lacking written description is withdrawn in response to Applicant's amendment.
- 3. The rejection of claims 1-5, 24-26, and 36 under 35 U.S.C. 103(a) as unpatentable over Fujitsa et al. and 22, 23, 27, and 28 as unpatentable over Fujita et al. in view of the '786 patent is withdrawn in response to Applicant's amendment requiring that the hedgehog antibodies inhibit expression of hedgehog. These claims are newly rejected under 35 U.S.C. 112, first paragraph, as adding new matter and as lacking enablement. Amendment of the claims to remove the new matter will result in reinstatement of the rejection of the claims under 35 U.S.C. 103(a), since *in vivo* treatment with an antibody, rendered obvious by Fujitsa et al., would inherently inhibit the action of hedgehog molecules produced by the surrounding cells.

New Grounds of Objection/Rejection

4. The amendment filed 24 March 2003 is objected to under 35 U.S.C. 132 because it introduces new matter into the disclosure. 35 U.S.C. 132 states that no amendment shall introduce new matter into the disclosure of the invention. The added material which is not supported by the original disclosure is as follows: the claims are now drawn to methods of

Art Unit: 1646

inhibiting expression using an antibody. Inhibition of expression by an antibody is not disclosed in the specification as originally filed.

Applicant is required to cancel the new matter in the reply to this Office Action.

- 5. Claims 1, 2, 4, 5, and 24-28 are rejected under 35 U.S.C. 112, first paragraph, as failing to comply with the written description requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor(s), at the time the application was filed, had possession of the claimed invention. This is a new matter rejection. As stated above, the specification as filed does not teach inhibition of expression using an antibody.
- 6. Claims 1, 2, 4, 5, and 24-28 are rejected under 35 U.S.C. 112, first paragraph, as failing to comply with the enablement requirement. The claim(s) contains subject matter that was not described in the specification in such a way as to enable one skilled in the art to which it pertains, or with which it is most nearly connected, to make and/or use the invention. As stated above, these claims now require inhibition of hedgehog expression by an antibody that interacts with hedgehog. Antibodies generally bind expressed protein; they do not affect the ability of a cell to make a given protein. Thus one of skill in the art would not predict, based on what is known in the art about antibody function, that inhibition of expression could be achieved with an antibody. The specification similarly provides no teachings to indicate that an antibody would inhibit expression. Thus the skilled artisan could not predictably achieve such inhibition and, without further guidance, it would require undue experimentation for the artisan to practice Applicant's invention as claimed.

Art Unit: 1646

NO CLAIM IS ALLOWED.

Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, **THIS ACTION IS MADE FINAL**. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the date of this final action.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Janet Andres, Ph.D., whose telephone number is (703) 305-0557. The examiner can normally be reached on Monday through Friday from 8:00 am to 5:30 pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Yvonne Eyler, Ph.D., can be reached at (703) 308-6564. The fax phone number for this group is (703) 872-9306 or (703) 872-9307 for after final communications.

Communications via internet mail regarding this application, other than those under U.S.C. 132 or which otherwise require a signature, may be used by the applicant and should be addressed to [yvonne.eyler@uspto.gov].

Art Unit: 1646

All Internet email communications will be made of record in the application file. PTO employees do not engage in Internet communications where there exists a possibility that sensitive information could be identified or exchanged unless the record includes a properly signed express waiver of the confidentiality requirements of 35 U.S.C. 122. This is more clearly set forth in the Interim Internet Usage Policy published in the Official Gazette of the Patent and Trademark Office on February 25, 1997 at 1195 OG 89.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the Group receptionist whose telephone number is (703) 308-0196.

Janet Andres, Ph.D. May 21, 2003

> YVONNE EYLER, PH.D SUPERVISORY PATENT EXAMINER TECHNOLOGY CENTER 1600